Abiopharma

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Lifecore Biomedical to be Added to Nasdaq Biotech Index

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287

Bristol Myers Squibb - Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

Viatris Provides Pipeline Update on Four Regulatory Milestones

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026